

A

Express Mail Label No.: EL599141892US

(Under 37 C.F.R. §1.53(b))

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Applications
Washington D.C. 20231

INVENTOR(S): SOPHIE M. CARPENTIER AND ALAIN F. CARPENTIER

- | | | | |
|----|-------------------------------------|---|---------------------------------|
| 1. | <input checked="" type="checkbox"/> | Fee Transmittal Form (Submit an original, and a duplicate for fee processing) | |
| 2. | <input checked="" type="checkbox"/> | Specification, including claims and abstract
[Total Pages | <input type="text" value="33"/> |
| 3. | <input checked="" type="checkbox"/> | Claims
[Total No. | <input type="text" value="92"/> |
| 4. | <input checked="" type="checkbox"/> | Drawing(s) (35 USC §113)
[Total Sheets (Figs.1 & 2) | <input type="text" value="2"/> |
| 5. | <input checked="" type="checkbox"/> | Signed Declaration
[Total Pages | <input type="text" value="2"/> |
| | a. | <input checked="" type="checkbox"/> Newly executed (original or copy) | |
| | b. | <input type="checkbox"/> Copy from a prior application (37 CFR §1.63(d)) | |

(Note Box 5 below)

DELETION OF INVENTOR(S)

Signed statement attached deleting inventor named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)

6. ☐ Incorporation By Reference (useable if Box 4b is checked.)
The entire disclosure of the prior application,
from which a copy of the oath or declaration is supplied
under Box 4b, is considered as being part of the
disclosure of the accompanying application and is
hereby incorporated by reference therein

7. ☐ Microfiche Computer Program
8. ☐ Nucleotide and/or Amino Acid Sequence Submission
9. ☒ Assignment Papers with recordation sheet (2 pages)

10. ☐ 37 CFR §3.73(b) Statement ☐ Power of Attorney
11. ☐ English Translation Document

18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____ / _____

19. The present application claims priority under 35 USC § 119 to U.S. Provisional Application No. _____, filed _____.

- | | | | | |
|------|-------------------------------------|---|--------------------------|-------------------------|
| 12. | <input type="checkbox"/> | Information Disclosure Statement (IDS)/PTO-1449 | <input type="checkbox"/> | Copies of IDS Citations |
| 13. | <input type="checkbox"/> | Preliminary Amendment | | |
| 14. | <input checked="" type="checkbox"/> | Return Receipt Postcard (MPEP 503) | | |
| 15. | <input type="checkbox"/> | Small Entity Statement(s) | | |
| 16. | <input type="checkbox"/> | Certified Copy of Priority Documents (s) | | |
| 17a. | <input type="checkbox"/> | Cancel in the application original claims _____ before calculating the filing fee | | |
| 17b. | <input type="checkbox"/> | Amend the specification by inserting before the first line the sentence: --This is a ____ Continuation, ____ Divisional, ____ Continuation-in-part, of application _____, filed _____ | | |
| 17c. | <input type="checkbox"/> | I hereby verify that the attached papers are a true copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was

Signed. I hereby verify that the papers are a true copy of the latest signed prior application number _____, filed _____ and further that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon. | | |
| 17d. | <input type="checkbox"/> | Other: | | |
| 17e. | <input type="checkbox"/> | Other | | |

JC879 U.S. PRO
 10/039367

 01/03/02

UTILITY PATENT
APPLICATION TRANSMITTAL
(Under 37 C.F.R. §1.53(b))

Docket No.: ECV-5608 Page 2 of 2
Title: TREATMENT OF BIOPROSTHETIC TYISSUES TO
MITIGATE POST IMPLANTATION CALCIFICATION
Express Mail Label No.: EL599141892US

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	92-20=	72	X \$18 =	\$1296
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	4 -3=	1	\$84 =	\$84
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ 280 =	\$
				BASIC FEE (37 CFR §1.16(a))	\$740
				TOTAL =	\$2120

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 501225 (Docket ~~***~~ 5608)
(For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. ☒ Fees required under 37 CFR §1.16
b. ☒ Fees required under 37 CFR §1.17
c. ☒ Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME	Debra D. Condino, Reg. No. 31,007
SIGNATURE	<i>Debra D Condino</i>
DATE	January 3, 2002

CORRESPONDENCE ADDRESS

Edwards Lifesciences LLC
Law Dept.
One Edwards Way
Irvine, California 92614
Telephone: (949) 250-6803 Fax: (949) 250-6850

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.10

I hereby certify that the above identified document is being deposited with the United States Postal Service as Express Mail No. EL599141892US in an envelope addressed to Assistant Commissioner for Patents, 2900 Crystal Drive, Arlington, VA 22202-3513 on Jan 3, 2002

By:

Michelle Brunet